Latest news

• Novartis strengthens case for its combination asthma drug

  However, it was still able to establish its next-generation of respiratory products – this includes Trelegy (vilanterol/umeclidinium/ fluticasone furoate), which brought in £139 in  Q3 and Nucala (mepolizumab), which brought

• GSK boosts outlook thanks to strong respiratory and vaccine sales

  New launches for respiratory products Nucala (mepolizumab) and Trelegy (vilanterol/umeclidinium/ fluticasone furoate) helped boost revenues in this area, bringing in £203m and £139m respectively.

• AZ builds case for its COPD triple as it chases GSK’s Trelegy

  After a slow start, Trelegy (vilanterol/umeclidinium/ fluticasone furoate) is showing signs of gathering momentum, with sales more than doubling to around $250m in the first half of this year.

• GSK’s Advair Diskus faces first generic in US

  It has also given GSK a bit more time to advance its three-drug COPD product Trelegy (fluticasone furoate/umeclidinium/vilanterol) as well as other new respiratory drugs – although some analysts

• Is GSK planning to exit the respiratory business?

  GSK has high hopes for three-drug combination Trelegy (fluticasone furoate/umeclidinium/vilanterol), but with third-quarter sales of £42m, that is still a long way off its blockbuster sales projections.